Form 20-F ☑
|
Form 40-F ☐
|
Yes ☐
|
No ☑
|
EXFO INC.
|
|
By: /s/ Germain Lamonde
Name: Germain Lamonde
Title: President and Chief Executive Officer
|
|
§
|
Sales increase 12.0% year-over-year to US$60.0 million
|
§
|
Adjusted EBITDA reaches US$4.9 million, or 8.1% of sales
|
§
|
Cash flows from operating activities total US$14.4 million
|
Q2 2017
|
Q1 2017
|
Q2 2016
|
||||||||||
Physical-layer sales
|
$
|
38,038
|
$
|
42,016
|
$
|
32,582
|
||||||
Protocol-layer sales
|
22,097
|
20,009
|
21,990
|
|||||||||
Foreign exchange losses on forward exchange contracts
|
(105
|
)
|
(240
|
)
|
(975
|
)
|
||||||
Total sales
|
$
|
60,030
|
$
|
61,785
|
$
|
53,597
|
||||||
Physical-layer bookings
|
$
|
34,031
|
$
|
44,090
|
$
|
34,874
|
||||||
Protocol-layer bookings
|
21,992
|
22,009
|
25,804
|
|||||||||
Foreign exchange losses on forward exchange contracts
|
(105
|
)
|
(240
|
)
|
(975
|
)
|
||||||
Total bookings
|
$
|
55,918
|
$
|
65,859
|
$
|
59,703
|
||||||
Book-to-bill ratio (bookings/sales)
|
0.93
|
1.07
|
1.11
|
|||||||||
Gross margin before depreciation and amortization*
|
$
|
37,041
|
$
|
38,972
|
$
|
34,693
|
||||||
61.7
|
%
|
63.1
|
%
|
64.7
|
%
|
|||||||
Other selected information:
|
||||||||||||
IFRS net earnings
|
$
|
1,008
|
$
|
3,303
|
$
|
3,963
|
||||||
Amortization of intangible assets
|
$
|
768
|
$
|
427
|
$
|
286
|
||||||
Stock-based compensation costs
|
$
|
353
|
$
|
258
|
$
|
314
|
||||||
Net income tax effect of the above items
|
$
|
(162
|
)
|
$
|
(64
|
)
|
$
|
(30
|
)
|
|||
Foreign exchange (gain) loss
|
$
|
272
|
$
|
(512
|
)
|
$
|
(1,101
|
)
|
||||
Adjusted EBITDA*
|
$
|
4,875
|
$
|
6,321
|
$
|
5,280
|
·
|
Sales and bookings. EXFO experienced strong demand for its optical and high-speed transport test solutions, mainly in the Americas, and continued traction of its LTB-8 rackmount platform for lab and manufacturing floor applications in the second quarter of 2017. Bookings decreased 6.3% year-over-year in the second quarter primarily because the company had secured two large monitoring and analytics orders in the second quarter of 2016, but witnessed delays in network operator budget releases and deal approvals in the most recent quarter. In the first half of 2017, bookings improved 3.0% year-over-year. In terms of segmented sales, Physical-layer sales surged 16.7% year-over-year in the second quarter of 2017, while Protocol-layer sales were flat. On a geographical basis, sales increased 14.5% year-over in the Americas, 12.4% in EMEA and 6.1% in Asia Pacific. Revenue distribution among these three regions in the second quarter amounted to 50% from the Americas, 29% from EMEA and 21% from Asia-Pacific. EXFO's top customer accounted for 10.0% of sales in the second quarter and 12.0% of sales in the first half of 2017, while the top three customers represented 16.6% and 19.2% of sales, respectively.
|
·
|
Profitability. EXFO generated adjusted EBITDA of US$4.9 million, or 8.1% of sales, in the second quarter of 2017 and US$11.2 million, or 9.2% of sales, after six months into fiscal 2017. EXFO also delivered US$14.4 million in cash flows from operating activities in the second quarter of 2017 to raise its cash position to US$52.4 million at the quarter end.
|
·
|
Innovation. EXFO launched several new products during the second quarter and following the quarter-end while taking part in two key industry events: Mobile World Congress and Optical Fiber Conference. Major product introductions included a 400 Gbit/s optical transport test solution, 200 Gbit/s optical spectrum analyzer and FTB-4 test platform—all focused on optical high-speed networking applications in the lab and field; an automated inspection probe for testing multifiber connectors in data centers and radio access networks (RANs); optical RF over OBSAI (open base station architecture initiative) link test capabilities to complement recently acquired optical RF over CPRI (common public radio interface) test technology for C-RAN deployments; and the company integrated Ookla's Speedtest technology into its MaxTester residential broadband test solution. Finally, EXFO received Frost & Sullivan's Market Share Leadership Award for the sixth consecutive year by building on its No. 1 position in the portable fiber-optic test equipment market.
|
Q2 2017
|
Q1 2017
|
Q2 2016
|
||||||||||
IFRS net earnings for the period
|
$
|
1,008
|
$
|
3,303
|
$
|
3,963
|
||||||
Add (deduct):
|
||||||||||||
Depreciation of property, plant and equipment
|
962
|
903
|
924
|
|||||||||
Amortization of intangible assets
|
768
|
427
|
286
|
|||||||||
Interest (income) expense
|
(9
|
)
|
(20
|
)
|
(470
|
)
|
||||||
Income taxes
|
1,521
|
1,962
|
1,364
|
|||||||||
Stock-based compensation costs
|
353
|
258
|
314
|
|||||||||
Foreign exchange (gain) loss
|
272
|
(512
|
)
|
(1,101
|
)
|
|||||||
Adjusted EBITDA for the period
|
$
|
4,875
|
$
|
6,321
|
$
|
5,280
|
||||||
Adjusted EBITDA in percentage of sales
|
8.1
|
%
|
10.2
|
%
|
9.9
|
%
|
As at
February 28,
2017
|
As at
August 31,
2016
|
|||||||
Assets
|
||||||||
Current assets
|
||||||||
Cash
|
$
|
48,343
|
$
|
43,208
|
||||
Short-term investments
|
4,074
|
4,087
|
||||||
Accounts receivable
|
||||||||
Trade
|
36,818
|
42,993
|
||||||
Other
|
5,435
|
2,474
|
||||||
Income taxes and tax credits recoverable
|
4,131
|
4,208
|
||||||
Inventories
|
33,039
|
33,004
|
||||||
Prepaid expenses
|
2,971
|
3,099
|
||||||
134,811
|
133,073
|
|||||||
Tax credits recoverable
|
34,159
|
34,594
|
||||||
Property, plant and equipment
|
36,843
|
35,978
|
||||||
Intangible assets (note 3)
|
7,034
|
3,391
|
||||||
Goodwill (note 3)
|
26,094
|
21,928
|
||||||
Deferred income tax assets
|
7,078
|
8,240
|
||||||
Other assets
|
435
|
589
|
||||||
$
|
246,454
|
$
|
237,793
|
|||||
Liabilities
|
||||||||
Current liabilities
|
||||||||
Accounts payable and accrued liabilities
|
$
|
37,803
|
$
|
37,174
|
||||
Provisions
|
258
|
299
|
||||||
Income taxes payable
|
545
|
971
|
||||||
Deferred revenue
|
11,335
|
9,486
|
||||||
49,941
|
47,930
|
|||||||
Deferred revenue
|
6,433
|
5,530
|
||||||
Deferred income tax liabilities
|
2,441
|
2,857
|
||||||
Other liabilities
|
30
|
75
|
||||||
58,845
|
56,392
|
|||||||
Shareholders' equity
|
||||||||
Share capital (note 5)
|
89,841
|
85,516
|
||||||
Contributed surplus
|
17,843
|
18,150
|
||||||
Retained earnings
|
130,620
|
126,309
|
||||||
Accumulated other comprehensive loss
|
(50,695
|
)
|
(48,574
|
)
|
||||
187,609
|
181,401
|
|||||||
$
|
246,454
|
$
|
237,793
|
Three months
ended
February 28,
2017
|
Six months
ended
February 28,
2017
|
Three months
ended
February 29,
2016
|
Six months
ended
February 29,
2016
|
|||||||||||||
Sales
|
$
|
60,030
|
$
|
121,815
|
$
|
53,597
|
$
|
108,829
|
||||||||
Cost of sales (1)
|
22,989
|
45,802
|
18,904
|
39,041
|
||||||||||||
Selling and administrative
|
21,255
|
42,850
|
19,565
|
39,817
|
||||||||||||
Net research and development
|
11,264
|
22,578
|
10,162
|
20,095
|
||||||||||||
Depreciation of property, plant and equipment
|
962
|
1,865
|
924
|
1,899
|
||||||||||||
Amortization of intangible assets
|
768
|
1,195
|
286
|
586
|
||||||||||||
Interest and other income
|
(9
|
)
|
(29
|
)
|
(470
|
)
|
(407
|
)
|
||||||||
Foreign exchange (gain) loss
|
272
|
(240
|
)
|
(1,101
|
)
|
(1,411
|
)
|
|||||||||
Earnings before income taxes
|
2,529
|
7,794
|
5,327
|
9,209
|
||||||||||||
Income taxes (note 7)
|
1,521
|
3,483
|
1,364
|
3,480
|
||||||||||||
Net earnings for the period
|
$
|
1,008
|
$
|
4,311
|
$
|
3,963
|
$
|
5,729
|
||||||||
Basic net earnings per share
|
$
|
0.02
|
$
|
0.08
|
$
|
0.07
|
$
|
0.11
|
||||||||
Diluted net earnings per share
|
$
|
0.02
|
$
|
0.08
|
$
|
0.07
|
$
|
0.10
|
||||||||
Basic weighted average number of shares outstanding (000's)
|
54,506
|
54,195
|
53,927
|
53,870
|
||||||||||||
Diluted weighted average number of shares outstanding (000's) (note 8)
|
55,681
|
55,341
|
54,615
|
54,575
|
Three months
ended
February 28,
2017
|
Six months
ended
February 28,
2017
|
Three months
ended
February 29,
2016
|
Six months
ended
February 29,
2016
|
|||||||||||||
Net earnings for the period
|
$
|
1,008
|
$
|
4,311
|
$
|
3,963
|
$
|
5,729
|
||||||||
Other comprehensive income (loss), net of income taxes
|
||||||||||||||||
Items that will not be reclassified subsequently to net earnings
|
||||||||||||||||
Foreign currency translation adjustment
|
2,019
|
(2,198
|
)
|
(2,204
|
)
|
(4,713
|
)
|
|||||||||
Items that may be reclassified subsequently to net earnings
|
||||||||||||||||
Unrealized gains/losses on forward exchange contracts
|
326
|
(235
|
)
|
50
|
(220
|
)
|
||||||||||
Reclassification of realized gains/losses on forward exchange contracts in net earnings
|
139
|
320
|
839
|
1,717
|
||||||||||||
Deferred income tax effect of gains/losses on forward exchange contracts
|
(100
|
)
|
(8
|
)
|
(242
|
)
|
(390
|
)
|
||||||||
Other comprehensive income (loss)
|
2,384
|
(2,121
|
)
|
(1,557
|
)
|
(3,606
|
)
|
|||||||||
Comprehensive income for the period
|
$
|
3,392
|
$
|
2,190
|
$
|
2,406
|
$
|
2,123
|
Six months ended February 29, 2016
|
||||||||||||||||||||
Share
capital
|
Contributed surplus
|
Retained earnings
|
Accumulated other comprehensive loss
|
Total
shareholders' equity
|
||||||||||||||||
Balance as at September 1, 2015
|
$
|
86,045
|
$
|
17,778
|
$
|
118,933
|
$
|
(52,005
|
)
|
$
|
170,751
|
|||||||||
Redemption of share capital (note 5)
|
(244
|
)
|
57
|
–
|
–
|
(187
|
)
|
|||||||||||||
Reclassification of stock-based compensation costs (note 5)
|
1,230
|
(1,230
|
)
|
–
|
–
|
–
|
||||||||||||||
Stock-based compensation costs
|
–
|
681
|
–
|
–
|
681
|
|||||||||||||||
Net earnings for the period
|
–
|
–
|
5,729
|
–
|
5,729
|
|||||||||||||||
Other comprehensive income (loss)
|
||||||||||||||||||||
Foreign currency translation adjustment
|
–
|
–
|
–
|
(4,713
|
)
|
(4,713
|
)
|
|||||||||||||
Changes in unrealized losses on forward exchange contracts, net of deferred income taxes of $390
|
–
|
–
|
–
|
1,107
|
1,107
|
|||||||||||||||
Total comprehensive income for the period
|
2,123
|
|||||||||||||||||||
Balance as at February 29, 2016
|
$
|
87,031
|
$
|
17,286
|
$
|
124,662
|
$
|
(55,611
|
)
|
$
|
173,368
|
Six months ended February 28, 2017
|
||||||||||||||||||||
Share
capital
|
Contributed surplus
|
Retained earnings
|
Accumulated other comprehensive loss
|
Total
shareholders' equity
|
||||||||||||||||
Balance as at September 1, 2016
|
$
|
85,516
|
$
|
18,150
|
$
|
126,309
|
$
|
(48,574
|
)
|
$
|
181,401
|
|||||||||
Issuance of share capital (notes 3 and 5)
|
3,490
|
–
|
–
|
–
|
3,490
|
|||||||||||||||
Reclassification of stock-based compensation costs (note 5)
|
835
|
(835
|
)
|
–
|
–
|
–
|
||||||||||||||
Stock-based compensation costs
|
–
|
528
|
–
|
–
|
528
|
|||||||||||||||
Net earnings for the period
|
–
|
–
|
4,311
|
–
|
4,311
|
|||||||||||||||
Other comprehensive income (loss)
|
||||||||||||||||||||
Foreign currency translation adjustment
|
–
|
–
|
–
|
(2,198
|
)
|
(2,198
|
)
|
|||||||||||||
Changes in unrealized gains/losses on forward exchange contracts, net of deferred income taxes of $8
|
–
|
–
|
–
|
77
|
77
|
|||||||||||||||
Total comprehensive income for the period
|
2,190
|
|||||||||||||||||||
Balance as at February 28, 2017
|
$
|
89,841
|
$
|
17,843
|
$
|
130,620
|
$
|
(50,695
|
)
|
$
|
187,609
|
Three months
ended
February 28,
2017
|
Six months
ended
February 28,
2017
|
Three months
ended
February 29,
2016
|
Six months
ended
February 29,
2016
|
|||||||||||||
Cash flows from operating activities
|
||||||||||||||||
Net earnings for the period
|
$
|
1,008
|
$
|
4,311
|
$
|
3,963
|
$
|
5,729
|
||||||||
Add (deduct) items not affecting cash
|
||||||||||||||||
Stock-based compensation costs
|
353
|
611
|
314
|
690
|
||||||||||||
Depreciation and amortization
|
1,730
|
3,060
|
1,210
|
2,485
|
||||||||||||
Deferred revenue
|
3,022
|
2,947
|
2,162
|
3,673
|
||||||||||||
Deferred income taxes
|
312
|
459
|
101
|
674
|
||||||||||||
Changes in foreign exchange gain/loss
|
107
|
(431
|
)
|
(615
|
)
|
(959
|
)
|
|||||||||
6,532
|
10,957
|
7,135
|
12,292
|
|||||||||||||
Changes in non-cash operating items
|
||||||||||||||||
Accounts receivable
|
5,160
|
2,602
|
11,305
|
9,281
|
||||||||||||
Income taxes and tax credits
|
(46
|
)
|
(390
|
)
|
1,211
|
933
|
||||||||||
Inventories
|
924
|
(324
|
)
|
(2,642
|
)
|
(5,868
|
)
|
|||||||||
Prepaid expenses
|
(156
|
)
|
102
|
(20
|
)
|
34
|
||||||||||
Other assets
|
(37
|
)
|
(24
|
)
|
10
|
203
|
||||||||||
Accounts payable, accrued liabilities and provisions
|
2,011
|
586
|
(1,644
|
)
|
1,731
|
|||||||||||
Other liabilities
|
1
|
1
|
(26
|
)
|
(54
|
)
|
||||||||||
14,389
|
13,510
|
15,329
|
18,552
|
|||||||||||||
Cash flows from investing activities
|
||||||||||||||||
Additions to short-term investments
|
(20
|
)
|
(316
|
)
|
‒
|
(21
|
)
|
|||||||||
Proceeds from disposal and maturity of short-term investments
|
298
|
298
|
501
|
501
|
||||||||||||
Purchases of capital assets
|
(1,656
|
)
|
(2,893
|
)
|
(927
|
)
|
(2,236
|
)
|
||||||||
Business combination (note 3)
|
–
|
(5,000
|
)
|
‒
|
‒
|
|||||||||||
(1,378
|
)
|
(7,911
|
)
|
(426
|
)
|
(1,756
|
)
|
|||||||||
Cash flows from financing activities
|
||||||||||||||||
Bank loan
|
–
|
–
|
153
|
468
|
||||||||||||
Redemption of share capital (note 5)
|
–
|
–
|
(186
|
)
|
(187
|
)
|
||||||||||
–
|
–
|
(33
|
)
|
281
|
||||||||||||
Effect of foreign exchange rate changes on cash
|
271
|
(464
|
)
|
674
|
477
|
|||||||||||
Change in cash
|
13,282
|
5,135
|
15,544
|
17,554
|
||||||||||||
Cash – Beginning of the period
|
35,061
|
43,208
|
27,874
|
25,864
|
||||||||||||
Cash – End of the period
|
$
|
48,343
|
$
|
48,343
|
$
|
43,418
|
$
|
43,418
|
||||||||
Supplementary information
|
||||||||||||||||
Income taxes paid
|
$
|
603
|
$
|
1,561
|
$
|
508
|
$
|
1,116
|
||||||||
Additions to capital assets
|
$
|
2,483
|
$
|
3,662
|
$
|
1,066
|
$
|
2,375
|
1
|
Nature of Activities and Incorporation
|
2
|
Basis of Presentation
|
3
|
Business Combination
|
Assets acquired
|
||||
Core technology
|
$
|
4,130
|
||
Other assets
|
236
|
|||
4,366
|
||||
Liability assumed
|
||||
Deferred income taxes
|
279
|
|||
Net identifiable assets acquired
|
4,087
|
|||
Goodwill
|
4,403
|
|||
Fair value of the total consideration transferred
|
$
|
8,490
|
Three months
ended February 28, 2017 |
Six months
ended February 28, 2017 |
|||||||
Balance – beginning of the period
|
$
|
21,418
|
$
|
21,928
|
||||
Business combination
|
4,403
|
4,403
|
||||||
Foreign currency translation adjustment
|
273
|
(237
|
)
|
|||||
Balance – end of the period
|
$
|
26,094
|
$
|
26,094
|
4
|
Financial Instruments
|
Level 1: |
Quoted prices (unadjusted) in active market for identical assets or liabilities
|
Level 2: |
Inputs other than quoted prices included within Level 1 that are observable for the asset and liability, either directly or indirectly
|
Level 3: |
Unobservable inputs for the asset or liability
|
As at February 28, 2017
|
As at August 31, 2016
|
|||||||||||||||
Level 1
|
Level 2
|
Level 1
|
Level 2
|
|||||||||||||
Financial assets
|
||||||||||||||||
Short-term investments
|
$
|
4,074
|
$
|
–
|
$
|
4,087
|
$
|
–
|
||||||||
Forward exchange contracts
|
$
|
–
|
$
|
646
|
$
|
–
|
$
|
980
|
||||||||
Financial liabilities
|
||||||||||||||||
Forward exchange contracts
|
$
|
–
|
$
|
491
|
$
|
–
|
$
|
1,120
|
Expiry dates
|
Contractual
amounts
|
Weighted average
contractual forward rates
|
|||||||
March 2017 to August 2017
|
$
|
12,000
|
1.3068
|
||||||
September 2017 to August 2018
|
12,700
|
1.3376
|
|||||||
September 2018 to December 2018
|
2,500
|
1.3585
|
|||||||
Total
|
$
|
27,200
|
1.3259
|
Expiry dates
|
Contractual
amounts
|
Weighted average
contractual forward rates
|
|||||||
March 2017 to August 2017
|
$
|
2,400
|
70.81
|
||||||
September 2017 to January 2018
|
2,000
|
70.76
|
|||||||
Total
|
$
|
4,400
|
70.79
|
Three months
ended
February 28,
2017
|
Six months
ended
February 28,
2017
|
Three months
ended
February 29,
2016
|
Six months
ended
February 29,
2016
|
|||||||||||||
Losses on forward exchange contracts
|
$
|
105
|
$
|
345
|
$
|
975
|
$
|
1,849
|
5
|
Share Capital
|
Six months ended February 29, 2016
|
||||||||||||||||||||
Multiple voting shares
|
Subordinate voting shares
|
|||||||||||||||||||
Number
|
Amount
|
Number
|
Amount
|
Total
amount
|
||||||||||||||||
Balance as at September 1, 2015
|
31,643,000
|
$
|
1
|
22,092,034
|
$
|
86,044
|
$
|
86,045
|
||||||||||||
Redemption of restricted share units
|
−
|
−
|
155,784
|
−
|
−
|
|||||||||||||||
Redemption of deferred share units
|
−
|
−
|
653
|
−
|
−
|
|||||||||||||||
Redemption of share capital
|
−
|
−
|
(200
|
)
|
(1
|
)
|
(1
|
)
|
||||||||||||
Reclassification of stock-based compensation costs to share capital upon exercise of stock awards
|
−
|
−
|
−
|
723
|
723
|
|||||||||||||||
Balance as at November 30, 2015
|
31,643,000
|
1
|
22,248,271
|
86,766
|
86,767
|
|||||||||||||||
Redemption of restricted share units
|
−
|
−
|
119,973
|
−
|
−
|
|||||||||||||||
Redemption of share capital
|
−
|
−
|
(62,442
|
)
|
(243
|
)
|
(243
|
)
|
||||||||||||
Reclassification of stock-based compensation costs to share capital upon exercise of stock awards
|
−
|
−
|
−
|
507
|
507
|
|||||||||||||||
Balance as at February 29, 2016
|
31,643,000
|
$
|
1
|
22,305,802
|
$
|
87,030
|
$
|
87,031
|
Six months ended February 28, 2017
|
||||||||||||||||||||
Multiple voting shares
|
Subordinate voting shares
|
|||||||||||||||||||
Number
|
Amount
|
Number
|
Amount
|
Total
amount
|
||||||||||||||||
Balance as at September 1, 2016
|
31,643,000
|
$
|
1
|
21,917,942
|
$
|
85,515
|
$
|
85,516
|
||||||||||||
Issuance of share capital (note 3)
|
−
|
−
|
793,070
|
3,490
|
3,490
|
|||||||||||||||
Redemption of restricted share units
|
−
|
−
|
88,371
|
−
|
−
|
|||||||||||||||
Reclassification of stock-based compensation costs to share capital upon exercise of stock awards
|
−
|
−
|
−
|
346
|
346
|
|||||||||||||||
Balance as at November 30, 2016
|
31,643,000
|
1
|
22,799,383
|
89,351
|
89,352
|
|||||||||||||||
Redemption of restricted share units
|
−
|
−
|
97,900
|
−
|
−
|
|||||||||||||||
Redemption of deferred share units
|
−
|
−
|
29,456
|
−
|
−
|
|||||||||||||||
Reclassification of stock-based compensation costs to share capital upon exercise of stock awards
|
−
|
−
|
−
|
489
|
489
|
|||||||||||||||
Balance as at February 28, 2017
|
31,643,000
|
$
|
1
|
22,926,739
|
$
|
89,840
|
$
|
89,841
|
6
|
Statements of Earnings
|
Three months
ended
February 28,
2017
|
Six months
ended
February 28,
2017
|
Three months
ended
February 29,
2016
|
Six months
ended
February 29,
2016
|
|||||||||||||
Gross research and development expenses
|
$
|
12,716
|
$
|
25,356
|
$
|
11,472
|
$
|
22,751
|
||||||||
Research and development tax credits and grants
|
(1,452
|
)
|
(2,778
|
)
|
(1,310
|
)
|
(2,656
|
)
|
||||||||
Net research and development expenses for the period
|
$
|
11,264
|
$
|
22,578
|
$
|
10,162
|
$
|
20,095
|
Three months
ended
February 28,
2017
|
Six months
ended
February 28,
2017
|
Three months
ended
February 29,
2016
|
Six months
ended
February 29,
2016
|
|||||||||||||
Inventory write-down for the period
|
$
|
482
|
$
|
976
|
$
|
609
|
$
|
1,456
|
Three months
ended
February 28,
2017
|
Six months
ended
February 28,
2017
|
Three months
ended
February 29,
2016
|
Six months
ended
February 29,
2016
|
|||||||||||||
Cost of sales
|
||||||||||||||||
Depreciation of property, plant and equipment
|
$
|
371
|
$
|
730
|
$
|
312
|
$
|
635
|
||||||||
Amortization of intangible assets
|
672
|
969
|
168
|
345
|
||||||||||||
1,043
|
1,699
|
480
|
980
|
|||||||||||||
Selling and administrative expenses
|
||||||||||||||||
Depreciation of property, plant and equipment
|
139
|
257
|
114
|
260
|
||||||||||||
Amortization of intangible assets
|
17
|
36
|
18
|
36
|
||||||||||||
156
|
293
|
132
|
296
|
|||||||||||||
Net research and development expenses
|
||||||||||||||||
Depreciation of property, plant and equipment
|
452
|
878
|
498
|
1,004
|
||||||||||||
Amortization of intangible assets
|
79
|
190
|
100
|
205
|
||||||||||||
531
|
1,068
|
598
|
1,209
|
|||||||||||||
$
|
1,730
|
$
|
3,060
|
$
|
1,210
|
$
|
2,485
|
|||||||||
Depreciation of property, plant and equipment
|
$
|
962
|
$
|
1,865
|
$
|
924
|
$
|
1,899
|
||||||||
Amortization of intangible assets
|
768
|
1,195
|
286
|
586
|
||||||||||||
Total depreciation and amortization expenses for the period
|
$
|
1,730
|
$
|
3,060
|
$
|
1,210
|
$
|
2,485
|
Three months
ended
February 28,
2017
|
Six months
ended
February 28,
2017
|
Three months
ended
February 29,
2016
|
Six months
ended
February 29,
2016
|
|||||||||||||
Salaries and benefits
|
$
|
29,244
|
$
|
58,022
|
$
|
27,794
|
$
|
54,758
|
||||||||
Stock-based compensation costs
|
353
|
611
|
314
|
690
|
||||||||||||
Total employee compensation for the period
|
$
|
29,597
|
$
|
58,633
|
$
|
28,108
|
$
|
55,448
|
Three months
ended
February 28,
2017
|
Six months
ended
February 28,
2017
|
Three months
ended
February 29,
2016
|
Six months
ended
February 29,
2016
|
|||||||||||||
Cost of sales
|
$
|
27
|
$
|
54
|
$
|
24
|
$
|
55
|
||||||||
Selling and administrative expenses
|
251
|
430
|
224
|
490
|
||||||||||||
Net research and development expenses
|
75
|
127
|
66
|
145
|
||||||||||||
Total stock-based compensation for the period
|
$
|
353
|
$
|
611
|
$
|
314
|
$
|
690
|
7
|
Income Taxes
|
Three months
ended
February 28,
2017
|
Six months
ended
February 28,
2017
|
Three months
ended
February 29,
2016
|
Six months
ended
February 29,
2016
|
|||||||||||||
Income tax provision at combined Canadian federal and provincial statutory tax rate (27%)
|
$
|
683
|
$
|
2,105
|
$
|
1,438
|
$
|
2,486
|
||||||||
Increase (decrease) due to:
|
||||||||||||||||
Foreign income taxed at different rates
|
(408
|
)
|
(580
|
)
|
(242
|
)
|
(400
|
)
|
||||||||
Non-deductible loss (non-taxable income)
|
(5
|
)
|
189
|
(274
|
)
|
(70
|
)
|
|||||||||
Non-deductible expenses
|
180
|
353
|
145
|
315
|
||||||||||||
Change in tax rates
|
64
|
(25
|
)
|
–
|
–
|
|||||||||||
Foreign exchange effect of translation of foreign subsidiaries in the functional currency
|
4
|
(118
|
)
|
251
|
101
|
|||||||||||
Utilization of previously unrecognized deferred income tax assets
|
(133
|
)
|
(289
|
)
|
(32
|
)
|
(32
|
)
|
||||||||
Unrecognized deferred income tax assets on temporary deductible differences and unused tax losses
|
1,130
|
1,980
|
330
|
1,342
|
||||||||||||
Other
|
6
|
(132
|
)
|
(252
|
)
|
(262
|
)
|
|||||||||
Income tax provision for the period
|
$
|
1,521
|
$
|
3,483
|
$
|
1,364
|
$
|
3,480
|
Three months
ended
February 28,
2017
|
Six months
ended
February 28,
2017
|
Three months
ended
February 29,
2016
|
Six months
ended
February 29,
2016
|
|||||||||||||
Current
|
$
|
1,209
|
$
|
3,024
|
$
|
1,263
|
$
|
2,806
|
||||||||
Deferred
|
312
|
459
|
101
|
674
|
||||||||||||
$
|
1,521
|
$
|
3,483
|
$
|
1,364
|
$
|
3,480
|
8
|
Earnings per Share
|
Three months
ended
February 28,
2017
|
Six months
ended
February 28,
2017
|
Three months
ended
February 29,
2016
|
Six months
ended
February 29,
2016
|
|||||||||||||
Basic weighted average number of shares outstanding (000's)
|
54,506
|
54,195
|
53,927
|
53,870
|
||||||||||||
Plus dilutive effect of (000's):
|
||||||||||||||||
Restricted share units
|
1,022
|
990
|
563
|
585
|
||||||||||||
Deferred share units
|
153
|
156
|
125
|
120
|
||||||||||||
Diluted weighted average number of shares outstanding (000's)
|
55,681
|
55,341
|
54,615
|
54,575
|
||||||||||||
Stock awards excluded from the calculation of diluted weighted average number of shares because their exercise price was greater than the average market price of the common shares (000's)
|
–
|
–
|
244
|
152
|
9
|
Subsequent Event
|
Three months
ended
February 28,
2017
|
Three months
ended
February 29,
2016
|
Six months
ended
February 28,
2017
|
Six months
ended
February 29,
2016
|
|||||||||||||
Sales
|
$
|
60,030
|
$
|
53,597
|
$
|
121,815
|
$
|
108,829
|
||||||||
Cost of sales(1)
|
22,989
|
18,904
|
45,802
|
39,041
|
||||||||||||
Selling and administrative
|
21,255
|
19,565
|
42,850
|
39,817
|
||||||||||||
Net research and development
|
11,264
|
10,162
|
22,578
|
20,095
|
||||||||||||
Depreciation of property, plant and equipment
|
962
|
924
|
1,865
|
1,899
|
||||||||||||
Amortization of intangible assets
|
768
|
286
|
1,195
|
586
|
||||||||||||
Interest and other income
|
(9
|
)
|
(470
|
)
|
(29
|
)
|
(407
|
)
|
||||||||
Foreign exchange (gain) loss
|
272
|
(1,101
|
)
|
(240
|
)
|
(1,411
|
)
|
|||||||||
Earnings before income taxes
|
2,529
|
5,327
|
7,794
|
9,209
|
||||||||||||
Income taxes
|
1,521
|
1,364
|
3,483
|
3,480
|
||||||||||||
Net earnings for the period
|
$
|
1,008
|
$
|
3,963
|
$
|
4,311
|
$
|
5,729
|
||||||||
Basic net earnings per share
|
$
|
0.02
|
$
|
0.07
|
$
|
0.08
|
$
|
0.11
|
||||||||
Diluted net earnings per share
|
$
|
0.02
|
$
|
0.07
|
$
|
0.08
|
$
|
0.10
|
||||||||
Other selected information:
|
||||||||||||||||
Gross margin before depreciation and amortization(2)
|
$
|
37,041
|
$
|
34,693
|
$
|
76,013
|
$
|
69,788
|
||||||||
Research and development:
|
||||||||||||||||
Gross research and development
|
$
|
12,716
|
$
|
11,472
|
$
|
25,356
|
$
|
22,751
|
||||||||
Net research and development
|
$
|
11,264
|
$
|
10,162
|
$
|
22,578
|
$
|
20,095
|
||||||||
Adjusted EBITDA(2)
|
$
|
4,875
|
$
|
5,280
|
$
|
11,196
|
$
|
10,566
|
(1)
|
The cost of sales is exclusive of depreciation and amortization, shown separately.
|
(2)
|
Refer to page 36 for non-IFRS measures.
|
Three months
ended
February 28,
2017
|
Three months
ended
February 29,
2016
|
Six months
ended
February 28,
2017
|
Six months
ended
February 29,
2016
|
|||||||||||||
Sales
|
100.0
|
%
|
100.0
|
%
|
100.0
|
%
|
100.0
|
%
|
||||||||
Cost of sales(1)
|
38.3
|
35.3
|
37.6
|
35.9
|
||||||||||||
Selling and administrative
|
35.4
|
36.5
|
35.2
|
36.6
|
||||||||||||
Net research and development
|
18.8
|
19.0
|
18.5
|
18.5
|
||||||||||||
Depreciation of property, plant and equipment
|
1.6
|
1.7
|
1.5
|
1.7
|
||||||||||||
Amortization of intangible assets
|
1.3
|
0.5
|
1.0
|
0.5
|
||||||||||||
Interest and other income
|
–
|
(0.9
|
)
|
–
|
(0.4
|
)
|
||||||||||
Foreign exchange (gain) loss
|
0.4
|
(2.0
|
)
|
(0.1
|
)
|
(1.3
|
)
|
|||||||||
Earnings before income taxes
|
4.2
|
9.9
|
6.3
|
8.5
|
||||||||||||
Income taxes
|
2.5
|
2.5
|
2.8
|
3.2
|
||||||||||||
Net earnings for the period
|
1.7
|
%
|
7.4
|
%
|
3.5
|
%
|
5.3
|
%
|
||||||||
Other selected information:
|
||||||||||||||||
Gross margin before depreciation and amortization(2)
|
61.7
|
%
|
64.7
|
%
|
62.4
|
%
|
64.1
|
%
|
||||||||
Research and development:
|
||||||||||||||||
Gross research and development
|
21.2
|
%
|
21.4
|
%
|
20.8
|
%
|
20.9
|
%
|
||||||||
Net research and development
|
18.8
|
%
|
19.0
|
%
|
18.5
|
%
|
18.5
|
%
|
||||||||
Adjusted EBITDA(2)
|
8.1
|
%
|
9.9
|
%
|
9.2
|
%
|
9.7
|
%
|
(1)
|
The cost of sales is exclusive of depreciation and amortization, shown separately.
|
(2)
|
Refer to page 36 for non-IFRS measures.
|
Three months
ended
February 28,
2017
|
Three months
ended
February 29,
2016
|
Six months
ended
February 28,
2017
|
Six months
ended
February 29,
2016
|
|||||||||||||
Physical-layer product line
|
$
|
38,038
|
$
|
32,582
|
$
|
80,054
|
$
|
70,059
|
||||||||
Protocol-layer product line
|
22,097
|
21,990
|
42,106
|
40,619
|
||||||||||||
60,135
|
54,572
|
122,160
|
110,678
|
|||||||||||||
Foreign exchange losses on forward exchange contracts
|
(105
|
)
|
(975
|
)
|
(345
|
)
|
(1,849
|
)
|
||||||||
Total sales
|
$
|
60,030
|
$
|
53,597
|
$
|
121,815
|
$
|
108,829
|
Three months
ended
February 28,
2017
|
Three months
ended
February 29,
2016
|
Six months
ended
February 28,
2017
|
Six months
ended
February 29,
2016
|
|||||||||||||
Physical-layer product line
|
$
|
34,031
|
$
|
34,874
|
$
|
78,121
|
$
|
73,752
|
||||||||
Protocol-layer product line
|
21,992
|
25,804
|
44,001
|
46,273
|
||||||||||||
56,023
|
60,678
|
122,122
|
120,025
|
|||||||||||||
Foreign exchange losses on forward exchange contracts
|
(105
|
)
|
(975
|
)
|
(345
|
)
|
(1,849
|
)
|
||||||||
Total bookings
|
$
|
55,918
|
$
|
59,703
|
$
|
121,777
|
$
|
118,176
|
Three months
ended
February 28,
2017
|
Three months
ended
February 29,
2016
|
Six months
ended
February 28,
2017
|
Six months
ended
February 29,
2016
|
|||||||||||||
Americas
|
50
|
%
|
49
|
%
|
53
|
%
|
52
|
%
|
||||||||
EMEA
|
29
|
29
|
26
|
27
|
||||||||||||
Asia-Pacific
|
21
|
22
|
21
|
21
|
||||||||||||
100
|
%
|
100
|
%
|
100
|
%
|
100
|
%
|
Expiry dates
|
Contractual
amounts
|
Weighted average
contractual forward rates
|
||||||
March 2017 to August 2017
|
$
|
12,000,000
|
1.3068
|
|||||
September 2017 to August 2018
|
12,700,000
|
1.3376
|
||||||
September 2018 to December 2018
|
2,500,000
|
1.3585
|
||||||
Total
|
$
|
27,200,000
|
1.3259
|
Expiry dates
|
Contractual
amounts
|
Weighted average
contractual forward rates
|
||||||
March 2017 to August 2017
|
$
|
2,400,000
|
70.81
|
|||||
September 2017 to January 2018
|
2,000,000
|
70.76
|
||||||
Total
|
$
|
4,400,000
|
70.79
|
Three months
ended
February 28,
2017
|
Three months
ended
February 29,
2016
|
Six months
ended
February 28,
2017
|
Six months
ended
February 29,
2016
|
|||||||||||||
IFRS net earnings for the period
|
$
|
1,008
|
$
|
3,963
|
$
|
4,311
|
$
|
5,729
|
||||||||
Add (deduct):
|
||||||||||||||||
Depreciation of property, plant and equipment
|
962
|
924
|
1,865
|
1,899
|
||||||||||||
Amortization of intangible assets
|
768
|
286
|
1,195
|
586
|
||||||||||||
Interest and other income
|
(9
|
)
|
(470
|
)
|
(29
|
)
|
(407
|
)
|
||||||||
Income taxes
|
1,521
|
1,364
|
3,483
|
3,480
|
||||||||||||
Stock-based compensation costs
|
353
|
314
|
611
|
690
|
||||||||||||
Foreign exchange (gain) loss
|
272
|
(1,101
|
)
|
(240
|
)
|
(1,411
|
)
|
|||||||||
Adjusted EBITDA for the period
|
$
|
4,875
|
$
|
5,280
|
$
|
11,196
|
$
|
10,566
|
||||||||
Adjusted EBITDA as a percentage of sales
|
8.1
|
%
|
9.9
|
%
|
9.2
|
%
|
9.7
|
%
|
Quarters ended
|
||||||||||||||||
February 28,
2017
|
November 30,
2016
|
August 31,
2016
|
May 31,
2016
|
|||||||||||||
Sales
|
$
|
60,030
|
$
|
61,785
|
$
|
62,858
|
$
|
60,896
|
||||||||
Cost of sales(1)
|
$
|
22,989
|
$
|
22,813
|
$
|
24,145
|
$
|
23,880
|
||||||||
Net earnings
|
$
|
1,008
|
$
|
3,303
|
$
|
2,252
|
$
|
919
|
||||||||
Basic and diluted net earnings per share
|
$
|
0.02
|
$
|
0.06
|
$
|
0.04
|
$
|
0.02
|
Quarters ended
|
||||||||||||||||
February 29,
2016
|
November 30,
2015
|
August 31,
2015
|
May 31,
2015
|
|||||||||||||
Sales
|
$
|
53,597
|
$
|
55,232
|
$
|
56,594
|
$
|
57,781
|
||||||||
Cost of sales(1)
|
$
|
18,904
|
$
|
20,137
|
$
|
21,975
|
$
|
22,281
|
||||||||
Net earnings
|
$
|
3,963
|
$
|
1,766
|
$
|
1,882
|
$
|
563
|
||||||||
Basic and diluted net earnings per share
|
$
|
0.07
|
$
|
0.03
|
$
|
0.03
|
$
|
0.01
|
(1)
|
The cost of sales is exclusive of depreciation and amortization.
|
1. |
Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of EXFO Inc. (the "issuer") for the interim period ended February 28, 2017.
|
2. |
No misrepresentation: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.
|
3. |
Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.
|
4. |
Responsibility: The issuer's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in Regulation 52-109 respecting Certification of Disclosure in Issuer's Annual and Interim Filings (c. V-1.1, r. 27), for the issuer.
|
5. |
Design: Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer and I have, as at the end of the period covered by the interim filings
|
(a) |
designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that
|
(i) |
material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and
|
(ii) |
information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
|
(b) |
designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.
|
5.1 |
Control framework: The control framework the issuer's other certifying officer and I used to design the issuer's ICFR is the Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
|
5.2 |
N/A
|
5.3 |
N/A
|
6. |
Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on December 1, 2016 and ended on February 28, 2017 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.
|
1. |
Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of EXFO Inc. (the "issuer") for the interim period ended February 28, 2017.
|
2. |
No misrepresentation: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.
|
3. |
Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.
|
4. |
Responsibility: The issuer's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in Regulation 52-109 respecting Certification of Disclosure in Issuer's Annual and Interim Filings (c. V-1.1, r. 27), for the issuer.
|
5. |
Design: Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer and I have, as at the end of the period covered by the interim filings
|
(a) |
designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that
|
(i) |
material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and
|
(ii) |
information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
|
(b) |
designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.
|
5.1 |
Control framework: The control framework the issuer's other certifying officer and I used to design the issuer's ICFR is the Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
|
5.2 |
N/A
|
5.3 |
N/A
|
6. |
Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on December 1, 2016 and ended on February 28, 2017 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.
|